Cancer- and chemotherapy-induced anemia.

Published

Journal Article

Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.

Full Text

Duke Authors

Cited Authors

  • Rodgers, GM; Becker, PS; Blinder, M; Cella, D; Chanan-Khan, A; Cleeland, C; Coccia, PF; Djulbegovic, B; Gilreath, JA; Kraut, EH; Matulonis, UA; Millenson, MM; Reinke, D; Rosenthal, J; Schwartz, RN; Soff, G; Stein, RS; Vlahovic, G; Weir, AB

Published Date

  • May 2012

Published In

Volume / Issue

  • 10 / 5

Start / End Page

  • 628 - 653

PubMed ID

  • 22570293

Pubmed Central ID

  • 22570293

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Language

  • eng

Conference Location

  • United States